Drug Stock Poised to Lose Half its Value After Dismal Data

Conatus Pharmaceuticals' fatty liver disease drug did not meet its main goals

by Patrick Martin

Published on Dec 6, 2018 at 9:14 AM

The shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) are down a whopping 50% in electronic trading, after the drug developer's mid-stage study of a treatment for fatty liver disease failed to meet its main goals. In response, Stifel downgraded the stock to "hold" from "buy," while slashing its price target to $4 from $10. In addition, three other brokerages chimed in with cuts of their own, including to $10 from $14 at Oppenheimer.

Should today's price action pan out, this would be CNAT's worst single-day loss ever, and the shares will hit a new annual low. Prior to today's drop, the stock had seemingly found support near the $4.20-$4.50 area, home to its post-bull gap level from early April. Conatus shares closed Tuesday at $4.50.

Prior to today, analysts were overwhelmingly bullish. All five of the brokerages in coverage rated CNAT a "strong buy." Furthermore, it's average 12-month price target sits all the way up at $12, territory the security has not traded near since early 2014.

Pessimism has been ramping up in the options pits, though, despite limited absolute volume. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), CNAT stock's 10-day put/call volume ratio of 0.33 ranks in the 95th annual percentile. While this shows that more calls than puts have been bought to open on an absolute basis, the rate of put buying relative to call buying has been quicker than usual.


a schaeffer's exclusive

5 NEW STOCK PICKS

We're celebrating 38 years with this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


What's Next for the American Wealth Gap
Porter Stansberry is predicting a major change in the American economic system.
GDP, Consumer Spending Data in Post-Fed Spotlight
Next week will feature the final second-quarter GDP and fresh housing market data
Oversold Pot Stock Catches a Lift
PRVB stock is eyeing its lowest close in months, while IGC stock is set for a big win
What's Next for the American Wealth Gap
Porter Stansberry is predicting a major change in the American economic system.